QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

NCT06749899 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

580

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)
Nasopharyngeal Cancer

Interventions

DRUG: QL1706
DRUG: Gemcitabine
DRUG: Cisplatin
RADIATION: Intensity-modulated radiotherapy

Sponsor

Sun Yat-Sen University Cancer Center

Collaborators

[object Object]